Daily non-political popular news in brief.

24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus

A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.

Read more »

Keywords: 24-week, course, interferon-alpha, therapy, prolongs, survival, patients, hepatitis, virus, week, interferon, alpha, prolong, patient, hepatiti, viru

« Previous | Next »

Similar news on "24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus":

1. Hepatitis C treatment reduces the virus but serious liver problems may progress
   11-06-2007 · EurekAlert!
   Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis, and were reported at the annual meeting of the American Association for the Study of Liver Disease
   Similar news · Read more »
   
2. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
   12-27-2007 · EurekAlert!
   As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus showed treatment with weight-based REBETOL® (ribavirin, USP) in combination with pegylated interferon alfa-2b achieved significantly higher rates of sustained virologic response and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day.
   Similar news · Read more »
   
3. New drug helps hepatitis C patients start antiviral therapy
   10-30-2006 · EurekAlert!
   A new drug that stimulates the production of blood platelets can enable patients infected with hepatitis C virus to take other antiviral medications they previously could not take to fight the disease, according to the results of a clinical trial led by a Duke University Medical Center researcher.
   Similar news · Read more »
   
4. Silymarin does not affect virus activity or ALT levels in
   02-01-2008 · EurekAlert!
   In a survey of patients with chronic hepatitis C who participated in a National Institute of Diabetes and Digestive and Kidney Diseases-sponsored long-term treatment trial for patients who had failed to respond previously to antiviral therapy, approximately 40 percent acknowledged to interviewers at the time of enrollment that they were currently using or had in the recent past used herbal products for health purposes.
   Similar news · Read more »
   
5. Rare case of dental patient-to-patient hepatitis B virus transmission recorded
   04-03-2007 · EurekAlert!
   Researchers have documented a case of hepatitis B virus (HBV) transmission between two patients at a dentist's office in the United States. While this kind of infection is exceedingly rare, universal vaccination against the virus would likely have prevented both cases, according to the authors of the case report and an accompanying commentary. Both appear in the May 1 issue of the Journal of Infectious Diseases, now available online.
   Similar news · Read more »
   
6. Cetuximab may prolong survival for head and neck cancer patients
   01-18-2007 · EurekAlert!
   Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
   Similar news · Read more »
   
7. MGH study examines impact of infection with both HIV and hepatitis C virus
   12-11-2006 · EurekAlert!
   In a report in the December issue of PLOS Medicine, a group of researchers from the Partners AIDS Research Center at Massachusetts General Hospital report one of the first studies of how HIV infection impacts immune system functions involved with hepatitis C virus control. Their findings suggest that beginning antiretroviral therapy earlier than is generally recommended may help preserve HCV control in patients infected with both viruses.
   Similar news · Read more »
   
8. Gene patenting -- steep cost for health care and patients
   05-07-2007 · EurekAlert!
   The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
   Similar news · Read more »
   
9. Systemic treatment before surgery for kidney cancer prolongs patients' survival
   11-09-2006 · EurekAlert!
   Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients' survival, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics heard on Thursday.
   Similar news · Read more »
   
10. Bevacizumab found to improve survival for patients with advanced breast cancer
    12-26-2007 · EurekAlert!
    Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
    Similar news · Read more »